Evidence method
Level · gp.fundamentals.debt_to_revenue
336.43% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIP · Mar 31, 2021
ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001023024-21-000012General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
1.28% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
37.91% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
9.54% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
109.92% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
63.34% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
5.58% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
5.44% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
3.43% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 89.07%
- Current
- 336.43%
- Delta
- 247.36%
- Previous
- 2.94%
- Current
- 1.28%
- Delta
- -1.66%
- Previous
- 7.32%
- Current
- 37.91%
- Delta
- 30.59%
- Previous
- 0.93%
- Current
- 9.54%
- Delta
- 8.60%
- Previous
- 29.17%
- Current
- 109.92%
- Delta
- 80.75%
- Previous
- 58.19%
- Current
- 63.34%
- Delta
- 5.15%
- Previous
- -7.68%
- Current
- 5.58%
- Delta
- 13.27%
- Previous
- 7.68%
- Current
- 5.44%
- Delta
- -2.23%
- Previous
- 6.21%
- Current
- 3.43%
- Delta
- -2.78%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIP Fundamental State →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · ANIP CAPEX_INTENSITY_DECREASED →Transitioned To · ANIP CASH_GENERATION_INCREASED →Transitioned To · ANIP GROWTH_INCREASED →Transitioned To · ANIP INVENTORY_PRESSURE_INCREASED →Transitioned To · ANIP MARGIN_INCREASED →Transitioned To · ANIP PROFITABILITY_INCREASED →Transitioned To · ANIP R_AND_D_INTENSITY_DECREASED →Transitioned To · ANIP SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.